Literature DB >> 3538789

Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine.

J Philippon, R Grob, F Dagreou, M Guggiari, M Rivierez, P Viars.   

Abstract

A prospective randomized double blind study was conducted in 70 patients suffering from subarachnoid haemorrhage, due to aneurysm rupture, to determine if the use of nimodipine reduces the severity of ischaemic deficits secondary to vasospasm. At the end of the study, two patients had severe deficit or died in the treated group, while 10 had a bad outcome in the placebo group. Angiographic vasospasm was not significantly different in its frequency or its severity between the two groups. However, the association of extensive and diffuse vasospasm was less frequent in the nimodipine group. This study confirms the effectiveness of Nimodipine in reducing the occurrence of neurological deficit due to vasospasm, even if this action is not observed in all cases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3538789     DOI: 10.1007/BF01456369

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  14 in total

1.  Cerebral arterial spasm. Part 4: in vitro effects of temperature, serotonin analogues, large nonphysiological concentrations of serotonin, and extracellular calcium and magnesium on serotonin-induced contractions of the canine basilar artery.

Authors:  G S Allen; C J Gross; L M Henderson; S N Chou
Journal:  J Neurosurg       Date:  1976-05       Impact factor: 5.115

2.  Pial arterial and venous reaction to intravenous infusion of nimodipine in cats.

Authors:  L M Auer
Journal:  J Neurosurg Sci       Date:  1982 Jul-Sep       Impact factor: 2.279

3.  Cerebral arterial spasm: part 10. Reversal of acute and chronic spasm in dogs with orally administered nifedipine.

Authors:  G S Allen; A L Bahr
Journal:  Neurosurgery       Date:  1979-01       Impact factor: 4.654

4.  Antifibrinolytic treatment in subarachnoid hemorrhage.

Authors:  M Vermeulen; K W Lindsay; G D Murray; F Cheah; A Hijdra; J P Muizelaar; M Schannong; G M Teasdale; H van Crevel; J van Gijn
Journal:  N Engl J Med       Date:  1984-08-16       Impact factor: 91.245

5.  Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings.

Authors:  M Nosko; B Weir; C Krueger; D Cook; S Norris; T Overton; D Boisvert
Journal:  Neurosurgery       Date:  1985-02       Impact factor: 4.654

6.  Early management of aneurysmal subarachnoid hemorrhage.

Authors:  B Ljunggren; L Brandt; G Sundbärg; H Säveland; S Cronqvist; H Stridbeck
Journal:  Neurosurgery       Date:  1982-09       Impact factor: 4.654

7.  Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog.

Authors:  P A Steen; L A Newberg; J H Milde; J D Michenfelder
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

8.  Prevention of symptomatic vasospasm by topically applied nimodipine.

Authors:  L M Auer; Z Ito; A Suzuki; H Ohta
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

9.  Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.

Authors:  G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

10.  Human pial vascular reactions to intravenous Nimodipine-infusion during EC-IC bypass surgery.

Authors:  L M Auer; R W Oberbauer; H V Schalk
Journal:  Stroke       Date:  1983 Mar-Apr       Impact factor: 7.914

View more
  51 in total

Review 1.  The role of calcium antagonists in the treatment of cerebrovascular disease.

Authors:  J J Murphy
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

Review 2.  Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  Nima Etminan; Mervyn D I Vergouwen; Don Ilodigwe; R Loch Macdonald
Journal:  J Cereb Blood Flow Metab       Date:  2011-02-02       Impact factor: 6.200

3.  Cerebral vasospasm after aneurysmal subarachnoid hemorrhage and traumatic brain injury.

Authors:  Saef Izzy; Susanne Muehlschlegel
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

Review 4.  Aneurysmal subarachnoid hemorrhage: prevention of delayed ischemic dysfunction with intravenous nimodipine.

Authors:  B Ljunggren; L Brandt; H Säveland; B Romner; T Ryman; K E Andersson
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

5.  Effects of HA1077, a novel calciumantagonistic spasmolytic agent on intracerebral arterioles of rats.

Authors:  M Takayasu; R G Dacey
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

Review 6.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

Review 7.  Treatment options for cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  M Kamran Athar; Joshua M Levine
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 8.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 9.  Vasodilators during cerebral aneurysm surgery.

Authors:  K Abe
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

10.  Acute surgery in intracranial aneurysms. Experience with 100 cases.

Authors:  J Bidziński; A Marchel; M Pastuszko
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.